|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
van't Veer LJ, Dai H, van de Vijver MJ, He
YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ,
Witteveen AT, et al: Gene expression profiling predicts clinical
outcome of breast cancer. Nature. 415:530–536. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Guarneri V and Conte P: Metastatic breast
cancer: Therapeutic options according to molecular subtypes and
prior adjuvant therapy. Oncologist. 14:645–656. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Greene FL: Breast tumours. TNM
classification of malignant tumours. Sobin LH, Gospodarowicz MK and
Wittekind C: (7th ed). Wiley-Blackwell. (Oxford). 181–93. 2009.
|
|
5
|
Hoff J, Portet R, Becue J, Fourtanier G
and Bugat R: Digestive tract metastases of breast cancers. Ann
Chir. 37:281–284. 1983.(In French). PubMed/NCBI
|
|
6
|
Borst MJ and Ingold JA: Metastatic
patterns of invasive lobular versus invasive ductal carcinoma of
the breast. Surgery. 114:637–641; discussion 641–642.
1993.PubMed/NCBI
|
|
7
|
Washington K and McDonagh D: Secondary
tumors of the gastrointestinal tract: Surgical pathologic findings
and comparison with autopsy survey. Mod Pathol. 8:427–433.
1995.PubMed/NCBI
|
|
8
|
Caramella E, Bruneton JN, Roux P, Aubanel
D and Lecomte P: Metastases of the digestive tract. Report of 77
cases and review of the literature. Eur J Radiol. 3:331–338.
1983.PubMed/NCBI
|
|
9
|
Wang Z, Spaulding B, Sienko A, Liang Y, Li
H, Nielsen G, Gong Yub G, Ro JY and Zhai Jim Q: Mammaglobin, a
valuable diagnostic marker for metastatic breast carcinoma. Int J
Clin Exp Pathol. 2:384–389. 2009.PubMed/NCBI
|
|
10
|
Takeda Y, Tsuta K, Shibuki Y, Hoshino T,
Tochigi N, Maeshima AM, Asamura H, Sasajima Y, Ito T and Matsuno Y:
Analysis of expression patterns of breast cancer-specific markers
(mammaglobin and gross cystic disease fluid protein 15) in lung and
pleural tumors. Arch Pathol Lab Med. 132:239–243. 2008.PubMed/NCBI
|
|
11
|
Raju U, Ma CK and Shaw A: Signet ring
variant of lobular carcinoma of the breast: A clinicopathologic and
immunohistochemical study. Mod Pathol. 6:516–520. 1993.PubMed/NCBI
|
|
12
|
Wick MR, Lillemoe TJ, Copland GT, Swanson
PE, Manivel JC and Kiang DT: Gross cystic disease fluid protein-15
as a marker for breast cancer: Immunohistochemical analysis of 690
human neoplasms and comparison with alpha-lactalbumin. Hum Pathol.
20:281–287. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schwarz RE, Klimstra DS and Turnbull AD:
Metastatic breast cancer masquerading as gastrointestinal primary.
Am J Gastroenterol. 93:111–114. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pectasides D, Psyrri A, Pliarchopoulou K,
Floros T, Papaxoinis G, Skondra M, Papatsibas G, Macheras A,
Athanasas G, Arapantoni-Datioti P and Economopoulos T: Gastric
metastases originating from breast cancer: Report of 8 cases and
review of the literature. Anticancer Res. 29:4759–4763.
2009.PubMed/NCBI
|
|
15
|
García-Becerra R, Santos N, Díaz L and
Camacho J: Mechanisms of resistance to endocrine therapy in breast
cancer: Focus on signaling pathways, miRNAs and genetically based
resistance. Int J Mol Sci. 14:108–145. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gutierrez MC, Detre S, Johnston S, Mohsin
SK, Shou J, Allred DC, Schiff R, Osborne CK and Dowsett M:
Molecular changes in tamoxifen-resistant breast cancer:
Relationship between estrogen receptor, HER-2 and p38
mitogen-activated protein kinase. J Clin Oncol. 23:2469–2476. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang YF, Liao YY, Li LQ, Xie SR, Xie YF
and Peng NF: Changes in ER, PR and HER2 receptors status after
neoadjuvant chemotherapy in breast cancer. Pathol Res Pract.
209:797–802. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pohlmann PR, Mayer IA and Mernaugh R:
Resistance to trastuzumab in breast cancer. Clin Cancer Res.
15:7479–7491. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guarneri V, Dieci MV, Barbieri E,
Piacentini F, Omarini C, Ficarra G, Bettelli S and Conte PF: Loss
of HER2 positivity and prognosis after neoadjuvant therapy in
HER2-positive breast cancer patients. Ann Oncol. 24:2990–2994.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hirata T, Shimizu C, Yonemori K, Hirakawa
A, Kouno T, Tamura K, Ando M, Katsumata N and Fujiwara Y: Change in
the hormone receptor status following administration of neoadjuvant
chemotherapy and its impact on the long-term outcome in patients
with primary breast cancer. Br J Cancer. 101:1529–1536. 2009.
View Article : Google Scholar : PubMed/NCBI
|
